Acumen Pharmaceuticals, Inc. (ABOS)

Import this data to Google Sheets with:

=jivedata("ABOS","financials")

Full statements spill as a table. For one cell: =jivedata("ABOS","Revenue") or =jivedata("ABOS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Acumen Pharmaceuticals, Inc.

ABOS • CIK 0001576885

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Research and Development Expense	$42,318	$93,798	$104,885	$86,787
General and Administrative Expense	$18,820	$20,219	$18,947	$18,630
Operating Income (Loss)	$-61,138	$-114,017	$-123,832	$-105,417
Operating Expenses	$61,138	$114,017	$123,832	$105,417
Net Income (Loss) Attributable to Parent	$-52,371	$-102,329	$-121,335	$-105,044
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-51,308	$-102,689	$-121,204	$-105,080
Weighted Average Number of Shares Outstanding, Basic	48,609,383	60,013,277	60,561,836	67,772,118
Investment Income, Interest	—	$14,317	$7,447	$5,136
InterestExpenseNonoperating	—	$4,068	$4,224	$4,318
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net	$-1,360	$1,590	$-460	$-310
Other Nonoperating Income (Expense)	$-83	$-151	$-266	$-135
Nonoperating Income (Expense)	$8,767	$11,688	$2,497	$373
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax	$1,063	$-360	$131	$-36

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$66,886	$35,627	$53,989	$59,443
Marketable Securities, Current	$176,636	$135,930	$62,876	$50,754
Marketable Securities, Noncurrent	$62,553	$59,968	$0	$0
Prepaid Expense and Other Assets, Current	$3,093	$6,749	$5,387	$5,316
Restricted Cash, Noncurrent	—	—	$231	$231
Assets, Current	$246,615	$178,306	$122,252	$115,513
Other Assets, Noncurrent	$221	$486	$350	$263
Assets	$310,125	$238,992	$122,833	$116,007
Long-term Debt	$29,897	$29,419	$22,396	$11,896
Other Liabilities, Noncurrent	—	$150	$0	$0
Liabilities	$43,152	$57,176	$52,403	$58,744
Accounts Payable, Current	$1,379	$5,648	$554	$13,379
Accrued Liabilities, Current	$6,339	$6,615	$10,072	$7,533
Short-term Debt	—	—	$8,765	$19,673
Liabilities, Current	$12,971	$27,607	$30,007	$46,848
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stock, Value, Issued	$6	$6	$6	$7
Additional Paid in Capital	$489,453	$506,985	$516,803	$557,186
Retained Earnings (Accumulated Deficit)	$-222,798	$-325,127	$-446,462	$-499,917
Accumulated Other Comprehensive Income (Loss), Net of Tax	$312	$-48	$83	$-13
Stockholders' Equity Attributable to Parent	$266,973	$181,816	$70,430	$57,263
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	300,000,000	300,000,000	300,000,000	300,000,000
Common Stock, Shares, Issued	57,910,461	60,094,083	60,575,369	72,314,714

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-52,371	$-102,329	$-121,335	$-105,044
Net Cash Provided by (Used in) Operating Activities	$-43,064	$-86,215	$-115,538	$-91,788
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	$-62,982	$-31,260	$18,361	$22,632
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$67,119	$35,859	$54,220	$75,856
Depreciation	$61	$63	$58	$50
Payments to Acquire Marketable Securities	$250,634	$170,731	$38,056	$40,823
Share-based Payment Arrangement, Noncash Expense	$6,145	$9,635	$9,852	$9,800
Proceeds from Sale and Maturity of Marketable Securities	$78,981	$218,774	$172,077	$119,777
Accretion (Amortization) of Discounts and Premiums, Investments	$3,121	$5,015	$809	$326
Payments to Acquire Productive Assets	$21	$16	$88	$0
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net	$-1,360	$1,590	$-460	$-310
Net Cash Provided by (Used in) Investing Activities	$-171,671	$48,027	$133,933	$78,954
Operating Lease, Right-of-Use Asset, Amortization Expense	$123	$115	$126	$133
Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss	$11	$97	$59	$62
Other Noncash Expense	—	$232	$0	$0
Proceeds from Issuance of Common Stock	$121,904	$7,938	$0	$0
Proceeds from Stock Options Exercised	$325	$0	$39	$174
Finance Lease, Principal Payments	—	$739	$0	$0
Payment, Tax Withholding, Share-based Payment Arrangement	—	$41	$73	$149
Net Cash Provided by (Used in) Financing Activities	$151,753	$6,928	$-34	$35,466
Income Taxes Paid, Net	$0	$0	$0	$0
Interest Paid, Excluding Capitalized Interest, Operating Activities	$169	$2,973	$2,936	$2,935
Increase (Decrease) in Prepaid Expense and Other Assets	$369	$3,656	$-1,362	$281
Increase (Decrease) in Other Operating Assets	$70	$-74	$-40	$-18
Increase (Decrease) in Accounts Payable	$-261	$4,269	$-5,094	$11,276
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	$2,989	$32	$3,301	$-4,200

Jive Data

Google Sheets add-onSheets Account

Import this data to Google Sheets with:

=jivedata("ABOS","financials")

Full statements spill as a table. For one cell: =jivedata("ABOS","Revenue") or =jivedata("ABOS","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Acumen Pharmaceuticals, Inc.

ABOS • CIK 0001576885

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Research and Development Expense	$42,318	$93,798	$104,885	$86,787
General and Administrative Expense	$18,820	$20,219	$18,947	$18,630
Operating Income (Loss)	$-61,138	$-114,017	$-123,832	$-105,417
Operating Expenses	$61,138	$114,017	$123,832	$105,417
Net Income (Loss) Attributable to Parent	$-52,371	$-102,329	$-121,335	$-105,044
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-51,308	$-102,689	$-121,204	$-105,080
Weighted Average Number of Shares Outstanding, Basic	48,609,383	60,013,277	60,561,836	67,772,118
Investment Income, Interest	—	$14,317	$7,447	$5,136
InterestExpenseNonoperating	—	$4,068	$4,224	$4,318
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net	$-1,360	$1,590	$-460	$-310
Other Nonoperating Income (Expense)	$-83	$-151	$-266	$-135
Nonoperating Income (Expense)	$8,767	$11,688	$2,497	$373
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax	$1,063	$-360	$131	$-36

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$66,886	$35,627	$53,989	$59,443
Marketable Securities, Current	$176,636	$135,930	$62,876	$50,754
Marketable Securities, Noncurrent	$62,553	$59,968	$0	$0
Prepaid Expense and Other Assets, Current	$3,093	$6,749	$5,387	$5,316
Restricted Cash, Noncurrent	—	—	$231	$231
Assets, Current	$246,615	$178,306	$122,252	$115,513
Other Assets, Noncurrent	$221	$486	$350	$263
Assets	$310,125	$238,992	$122,833	$116,007
Long-term Debt	$29,897	$29,419	$22,396	$11,896
Other Liabilities, Noncurrent	—	$150	$0	$0
Liabilities	$43,152	$57,176	$52,403	$58,744
Accounts Payable, Current	$1,379	$5,648	$554	$13,379
Accrued Liabilities, Current	$6,339	$6,615	$10,072	$7,533
Short-term Debt	—	—	$8,765	$19,673
Liabilities, Current	$12,971	$27,607	$30,007	$46,848
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stock, Value, Issued	$6	$6	$6	$7
Additional Paid in Capital	$489,453	$506,985	$516,803	$557,186
Retained Earnings (Accumulated Deficit)	$-222,798	$-325,127	$-446,462	$-499,917
Accumulated Other Comprehensive Income (Loss), Net of Tax	$312	$-48	$83	$-13
Stockholders' Equity Attributable to Parent	$266,973	$181,816	$70,430	$57,263
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	300,000,000	300,000,000	300,000,000	300,000,000
Common Stock, Shares, Issued	57,910,461	60,094,083	60,575,369	72,314,714

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-52,371	$-102,329	$-121,335	$-105,044
Net Cash Provided by (Used in) Operating Activities	$-43,064	$-86,215	$-115,538	$-91,788
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	$-62,982	$-31,260	$18,361	$22,632
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$67,119	$35,859	$54,220	$75,856
Depreciation	$61	$63	$58	$50
Payments to Acquire Marketable Securities	$250,634	$170,731	$38,056	$40,823
Share-based Payment Arrangement, Noncash Expense	$6,145	$9,635	$9,852	$9,800
Proceeds from Sale and Maturity of Marketable Securities	$78,981	$218,774	$172,077	$119,777
Accretion (Amortization) of Discounts and Premiums, Investments	$3,121	$5,015	$809	$326
Payments to Acquire Productive Assets	$21	$16	$88	$0
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net	$-1,360	$1,590	$-460	$-310
Net Cash Provided by (Used in) Investing Activities	$-171,671	$48,027	$133,933	$78,954
Operating Lease, Right-of-Use Asset, Amortization Expense	$123	$115	$126	$133
Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss	$11	$97	$59	$62
Other Noncash Expense	—	$232	$0	$0
Proceeds from Issuance of Common Stock	$121,904	$7,938	$0	$0
Proceeds from Stock Options Exercised	$325	$0	$39	$174
Finance Lease, Principal Payments	—	$739	$0	$0
Payment, Tax Withholding, Share-based Payment Arrangement	—	$41	$73	$149
Net Cash Provided by (Used in) Financing Activities	$151,753	$6,928	$-34	$35,466
Income Taxes Paid, Net	$0	$0	$0	$0
Interest Paid, Excluding Capitalized Interest, Operating Activities	$169	$2,973	$2,936	$2,935
Increase (Decrease) in Prepaid Expense and Other Assets	$369	$3,656	$-1,362	$281
Increase (Decrease) in Other Operating Assets	$70	$-74	$-40	$-18
Increase (Decrease) in Accounts Payable	$-261	$4,269	$-5,094	$11,276
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	$2,989	$32	$3,301	$-4,200

Acumen Pharmaceuticals, Inc.

S T A T E M E N T S O F O P E R A T I O N S A N D C O M P R E H E N S I V E L O S S

B A L A N C E S H E E T S

S T A T E M E N T S O F C A S H F L O W S

Acumen Pharmaceuticals, Inc.

S T A T E M E N T S O F O P E R A T I O N S A N D C O M P R E H E N S I V E L O S S

B A L A N C E S H E E T S

S T A T E M E N T S O F C A S H F L O W S